new pathways to discovery - home | fnih 2013 annual report.pdfforging uncommon collaborations a new...

New Pathways to Discovery

2013 Summary Annual Report

WHO WE ARE

The Foundation for the National Institutes of Health (FNIH) is an agile

team of biomedical scientists, program managers and fundraisers.

We work with a large network of forward-thinking leaders and

organizations to seek new knowledge and apply it to improve health,

lengthen life and reduce illness and disability. We orchestrate

productive research collaborations, incubate new research models and

channel resources for maximum impact. In all we do, we support the

mission of the National Institutes of Health, the largest biomedical

research agency in the world, as it works to turn discovery into health.

ABOUT THE COVER

Today’s biomedical research, which increasingly looks at diseases and conditions from a molecular level,

is devoting deep attention to pathways and networks such as the neural network depicted here. Just as

biological systems continually create new pathways to make more efficient connections, the Foundation for

the National Institutes of Health is creating new pathways and new inroads for managing the complex

alliances that thread through the research community, both public and private.

Biomedical research never stands still. It is a field driven by the intellect and curiosity of

scientists whose discoveries can enhance and protect the lives of people all over the world.

Today, spurred by knowledge generated by the thousands of studies supported by the National

Institutes of Health (NIH), we are experiencing an awe-inspiring era of scientific breakthroughs

and revolutionary insights into the causes and potential solutions to disease and disability.

Paradoxically, NIH, America’s premier biomedical research institution, continues to cope

with constrained budgets that critically erode our country’s ability to tap this remarkable

opportunity. Industry and academia are not immune from similar challenges. As NIH

Director Dr. Francis Collins wrote in the Washington Post in December 2013, we are “at a

critical juncture—a moment of exceptional opportunities that demand exceptional attention

if their promise is to be fully realized.”

An important game-changing strategy, one that helps redefine the landscape of biomedical

research, one that blends priorities and mission, is helping to address these challenges.

Creating alliances and partnerships that bring all the key players together—government,

industry, the private sector, patient advocates and academic researchers—helps the

biomedical community continue to take advantage of the unprecedented scientific

opportunities now available. The Foundation for the National Institutes of Health (FNIH)

is ideally positioned to create and manage complex collaborative efforts that streamline

pathways to discovery and implementation for progress in pursuit of greater knowledge that

supports the mission of the NIH—“turning discovery into health.”

On these pages you will read about FNIH initiatives to find new biological markers of disease,

to better prevent and treat traumatic brain injuries, to confront malnutrition and intestinal

disorders in children of the world’s developing nations and much more. The FNIH is working

to build a legacy of success. We are deeply proud of our accomplishments over the past

year and we are even more excited about the years to come.

Letter from the Chairman and President

CHARLES A. SANDERS, M.D.

CHAIRMAN

CHARLES A. SANDERS, M.D.

CHAIRMAN

MARIA C. FREIRE, PH.D.

PRESIDENT

MARIA C. FREIRE, PH.D.

PRESIDENT

FNIH At-a-Glance

OUR PARTNERSHIPS

Every day, the FNIH forges new models of

collaboration where all partners can contribute

and thrive. Our collective impact is much

greater than what any single organization

could achieve on its own.

Corporations

Foundations & Nonprofits

U.S. Government

Agencies

WHAT WE DO

The FNIH stands at the center of a wide portfolio of initiatives focused on a shared goal:

advancing biomedical science to improve lives and supporting the mission of the NIH.

RESEARCH PARTNERSHIPS — We develop collaborations with top experts from government,

industry, academia and the not-for-profit sector and provide a neutral environment where we can

work productively toward a common goal. Examples include:

• Portfolio Supporting NIH Research — Supporting and raising funds for multiple projects

initiated by the NIH, while also convening the right partners within and outside of the NIH.

• Global Health — Coordinating and operating more than 50 collaborative projects in over

33 countries, including the Grand Challenges in Global Health (GCGH) supported by the

Bill & Melinda Gates Foundation.

• Biomarkers Consortium — Initiating and managing more than 16 projects funded with over

$50 million in private dollars, designed to discover, develop and qualify biological markers to

support new drug development, preventive medicine and medical diagnostics.

SYMPOSIA, EVENTS & EXHIBITS — We organize and facilitate more than 60 events each year,

creating a forum for innovative thinkers in biomedical sciences to share ideas and engage the public

in disease and health awareness.

FELLOWSHIPS & AWARDS — We provide funding and training for early-career scientists, along

with support and recognition for researchers whose findings have advanced biomedical science.

PROGRAM EXAMPLES

NIH RESEARCH:

The Alzheimer’s

Disease Neuroimaging

Initiative created

a new standard

for cross-sector

collaboration and data

sharing (see page 5).

GLOBAL HEALTH:

Novel approach

to control disease-

spreading mosquitoes

(see page 9).

BIOMARKERS

CONSORTIUM:

The I-SPY 2 Breast

Cancer Trial is

accelerating the

development of

targeted therapies

(see page 5).

EXHIBIT:

The Smithsonian

exhibition, Genome:

Unlocking Life’s Code at

the Natural Museum of

History, opened in June

2013 to celebrate the

10th anniversary of

the sequencing of the

human genome.

AWARD:

The Lurie Prize

in Biomedical

Sciences recognizes

outstanding

achievement by a

promising scientist

age 52 or younger

(see more at fnih.org).

Individuals

Academia

FNIH

New pathways for discovery. Bold new thinking is urgently needed to take on society’s greatest research challenges to improve health. We are uniquely positioned to help. This is true, in part, because we keep good company—we have built collaborations with some of the most advanced thinkers in the world. And, we have the know-how to make these collaborations thrive, creating environments that are open and neutral, garnering the necessary resources and developing new models.

P. 4 2013 Summary Annual Report

A Unifying Force: Forging Uncommon Collaborations

A new collaboration focuses on traumatic brain injury The FNIH has joined with the NIH and the National Football League—a founding

partner, thanks to a $30 million donation—to form the Sports and Health

Research Program (SHRP), which has taken on brain injury as its first challenge,

including the study of the degenerative brain disease known as chronic traumatic

encephalopathy, or CTE.

CTE results from repeated trauma to the brain and can lead to dementia,

aggression, confusion and depression. Evidence of CTE has been found in the

brains of deceased boxers, football players and other athletes. SHRP is bringing

together researchers to define criteria for diagnosing CTE in brain tissue and

also to determine whether the first signs of CTE can be diagnosed earlier in life

through neuroimaging. In 2013, SHRP supported two major cooperative projects

involving top CTE and brain injury researchers to understand long-term changes

in the brain after head injury or concussions. Six additional pilot projects are

working on new ways to diagnose and treat athletes who suffer concussions.

SHRP’s work has critical implications for the 1.7 million Americans who suffer

traumatic brain injuries each year, including amateur and professional athletes

and combat soldiers.

New Pathways to Discovery P. 5

Unprecedented data sharing in Alzheimer’s research As the Alzheimer’s Disease Neuroimaging

Initiative (ADNI) approaches the end of its first

decade, the partnership remains a gold standard for

how academic, industry, advocacy and government

partners can, together, advance biomedical

research. Involving more than 25 partners

coordinated by the FNIH, ADNI created an online,

open-access database and image archive for all

information collected by researchers.

In ADNI phase 1, this included MRI and PET

scans, cerebrospinal fluid and other biosamples

from 1,500 participants. Making the information

available immediately helps speed everyone’s

progress in identifying the biological markers (or

biomarkers) that can help trace the progression

from normal to mild cognitive impairment to

Alzheimer’s Disease—the key to more accurate

diagnosis and early intervention. ADNI data have

provided the basis for numerous clinical trials and

disease-modeling efforts. Several nations are now

using similar approaches.

Phase 2, which will continue through 2015,

follows phase 1 participants and has enrolled

an additional 750 people. The study has also

expanded to include genetic testing, including

whole-genome sequencing for more than

800 participants.

A more efficient model to identify effective breast cancer drugsDrugs such as tamoxifen and Herceptin®

(trastuzumab) target specific characteristics of

breast cancer cells. But they do not help all women.

The I-SPY 2 TRIAL, supported by the FNIH

Biomarkers Consortium, created a way to evaluate

multiple novel anti-cancer compounds in a

single clinical trial structure, evaluating the

effectiveness of the new treatment by measuring

the shrinkage of the tumor prior to surgery. The

trial assigns women with high-risk breast cancers

to new treatments according to specific genetic

or biological traits of that tumor, using adaptive

randomization to improve these assignments

within the trial and hasten the time to market for

successful drugs.

Since 2010, seven compounds from five

pharmaceutical companies have been part of

I-SPY 2, of which two—neratinib and veliparib—

have moved into wider testing (I-SPY 3).

Now a flourishing program, FNIH has turned

I-SPY 2 over to QuantumLeap Healthcare

Collaborative, a not-for-profit working with the

University of California, San Francisco.


Channeling Resources: Achieving High-Impact Insights Worldwide

Insights into improving health for children in developing nations Young children in resource-poor areas are often caught in a cycle of inadequate

nutrition and frequent episodes of diarrhea caused by living in unsanitary conditions.

Enteric (intestinal) diseases often undo the benefits of sufficient nutrition, leading to

lifelong consequences, such as stunted growth and impaired cognitive development.

The $40 million MAL-ED Network, a collaborative project supported by the Bill &

Melinda Gates Foundation and managed by the FNIH in collaboration with the NIH

Fogarty International Center, supports researchers at eight field sites in Africa, Asia

and South America, who have been following more than 1,600 children (more than

200 at each site) since birth to understand how enteric pathogens, nutrition and

other environmental factors are linked to physical growth, cognitive development

and vaccine response.

Identifying biomarkers that predict growth faltering and/or impaired cognitive

development will inform development of strategies for timely intervention. For

example, MAL-ED recently found that elevated levels of three substances in the

stool of infants may correlate with poorer growth over the subsequent six months,

a result consistent in all eight sites, despite environmental differences. These

biomarkers may hold promise to help identify children at greatest risk.


New targets for intervening in pulmonary disease Chronic Obstructive Pulmonary Disease

(COPD)—which includes chronic bronchitis

and emphysema—affects more than 12 million

Americans and is the country’s third leading

cause of death. The disease progresses over

time, suggesting that there may be points for

early intervention to prevent full-blown COPD

from developing. However, we do not understand

the disease’s clinical course well enough to

make that happen.

The SPIROMICS (SubPopulations and

InteRmediate Outcome Measures in COPD

Study) program brings together the National Heart,

Lung and Blood Institute, the Food and Drug

Administration, industry partners and multiple

researchers across the country. The study is

now enrolling subjects with COPD at 11 sites

nationally and collecting blood samples, images,

lung function tests and genetic information to

determine disease subgroups and to identify

biomarkers of disease progression and severity

that will be useful as outcome measures in future

clinical trials. FNIH coordinates the SPIROMICS

External Scientific Board and hosted its meeting

in the summer of 2013.

The first medical definition for age-related muscle lossAs people age, they lose skeletal muscle, which

eventually can make them weaker, slower, more

prone to fall and more dependent—at great cost

to the healthcare system and society in general.

This condition, called sarcopenia, affects nearly

1 in 3 people over 60 and half of those over

age 80. At the moment, there is no standard for

the diagnosis of sarcopenia, which limits our

ability to understand how it develops and how it

might be treated or prevented.

The FNIH Biomarkers Consortium Sarcopenia

Project recently generated the first-ever, evidence-

based definition for sarcopenia, bringing together

the National Institute on Aging, the National

Institute of Arthritis and Musculoskeletal and Skin

Diseases, academic institutions, the Food and Drug

Administration, advocacy groups and five industry

partners to analyze data from nine long-term

epidemiologic studies involving more than 10,000

healthy people.

FNIH presented the definition in 2012 at a

Sarcopenia Consensus Summit and five papers will

be published in the spring of 2014. Approaching

sarcopenia as a medical condition, rather than a

natural outcome of aging, holds great promise for

improving the lives of older people.


Transformative Models: Shaping the Future of Biomedicine

Novel approaches to evaluate urgently needed antibiotics The threat posed by bacterial infections grows, as more strains develop

resistance to the current arsenal of antibiotics. Yet, in 2010 regulatory approval

for new antibiotics stalled, largely because the endpoints (outcome measures)

used to judge effectiveness have been based on antiquated studies.

The FNIH Biomarkers Consortium helped establish consensus on what

endpoints should be used in drug trials for Community-Acquired Bacterial

Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections

(ABSSSI). Partners include the Food and Drug Administration, the NIH’s National

Institute of Allergy and Infectious Diseases, the Infectious Diseases Society of

America, pharmaceutical companies, biotechnology companies and academic

researchers. The team identified two patient-reported outcome measures—

symptom improvement within 3 to 5 days for pneumonia and control of lesion

spread within 2 to 3 days for skin infection—that have been incorporated into

regulatory decision-making criteria and clinical trials.

One new antibiotic has been approved for pneumonia and three for skin

infection have cleared phase III testing—the result of well-designed clinical trials

that drew on FNIH work. A full set of recommended outcome measures is under

development, with completion expected by mid-2014.


A biological approach to stopping dengue fever Found in 100 countries, with no vaccine and no

cure, the mosquito-borne viral disease known as

dengue fever is a significant global health threat.

Using insecticides to control populations of the

female Aedes aegypti mosquito, which spreads the

virus, has failed to stop dengue; in fact, incidence

has increased 30-fold in the past 50 years.

The FNIH’s Grand Challenges in Global

Health, an initiative funded by the Bill & Melinda

Gates Foundation, is supporting a global network

of researchers who have found that infecting the

mosquitoes with Wolbachia, a common

bacterium found in many insects, can reduce

mosquitoes’ ability to transmit the virus.

The method has shown great promise

through a series of test releases in Australia

and additional trials are underway in Vietnam,

Indonesia and Brazil. Eliminate Dengue is one

of several projects that are part of the FNIH’s

Vector-based Control of Transmission: Discovery

Research (VCTR) program, an offshoot of the

Grand Challenges Initiative.

New inspiration for research on gender and Alzheimer’sIn early 2013, the FNIH came together with the

Geoffrey Beene Foundation Alzheimer’s Initiative,

to initiate a challenge to researchers worldwide,

to better understand gender-based differences in

the early cognitive decline that leads to Alzheimer’s

Disease. Women have a greater risk of developing

Alzheimer’s, partly because they live longer than

men; however, we know little else about differences

in how the disease affects the sexes.

Researchers were invited to “mine the

data”—including those available through the

Alzheimer’s Disease Neuroimaging Initiative

(ADNI)—and present their own hypotheses. In

November 2013, after a strict scientific and

technical evaluation, Enrico Glaab, Ph.D., a

researcher at the Luxembourg Centre for Systems

Biomedicine, was selected as the winner. He

received $50,000 to continue his study of USP9Y,

a protein that is expressed at different levels in

men’s and women’s brains and may afford men

some protection. The decision was so close,

however, that one of the contest’s sponsors,

Sanofi, offered $50,000 to fund the second-place

winners, Kimberly Glass, Ph.D., and John

Quackenbush, Ph.D., of the Dana-Farber Cancer

Institute.


2013 REVENUES

Contributions ____________ 95%

Other Revenue ____________ 3%

Grants ____________________ 2%

2013 EXPENSES

Research Partnerships ___ 90%

Management &

Fundraising _______________ 6%

Education, Events

& Awards _________________ 4%

Financial Highlights

REVENUE AND SUPPORT 2013 2012

Contributions $57,747,975 $57,116,586

Grants 887,026 1,338,963

Administrative fee 333,361 260,551

Government appropriations 500,000 514,000

Investment earnings 337,389 247,254

In-kind contributions 589,208 250,927

Donated services 43,000 41,000

Other revenue 150,775 343,501

Reduction of future pledges (214,788) (1,275,000)

TOTAL REVENUE AND SUPPORT $60,373,946 $58,837,782

EXPENSES AND CHANGES IN NET ASSETS

PROGRAM SERVICES

Fellowships and training programs $1,381,328 $1,325,295

Memorials, awards and events 1,299,278 1,246,180

Capital projects 38,754 35,100

Research partnerships 55,290,526 45,183,190

TOTAL PROGRAM SERVICES $58,009,886 $47,789,765

SUPPORTING SERVICES

Management and general $3,352,175 $3,105,327

Fundraising 104,008 145,093

TOTAL SUPPORTING SERVICES $3,456,183 $3,250,420

TOTAL EXPENSES $61,466,069 $51,040,185

CHANGE IN NET ASSETS $(1,092,123) $7,797,597

NET ASSETS BEGINNING OF YEAR 92,230,541 84,432,944

NET ASSETS AT END OF YEAR $91,138,418 $92,230,541

The Foundation's audited financial statements are available on request.

Our Donors


$5,000,000+

Bill & Melinda Gates Foundation 12

McKnight Brain Research Foundation 8

$2,500,000 – $4,999,999

Genentech, Inc. 7

Pfizer Inc 16

$1,000,000 – $2,499,999

Amgen, Inc. 11

Eli Lilly and Company 14

Johnson & Johnson 13

Merck Sharp & Dohme Corp. 16

Novartis Pharmaceuticals Corporation 14

$500,000 – $999,999

Boehringer Ingelheim Pharmaceuticals, Inc. 5

Bristol-Myers Squibb 14

National Institutes of Health 18

Newport Foundation

Pharmaceutical Research and Manufacturers of America 9

The Safeway Foundation 3

Sanofi 12

Takeda Pharmaceutical Company Limited 5

$250,000 – $499,999

AbbVie Inc.

Alzheimer’s Association 9

Biogen Idec 3

The Coca-Cola Company 6

GlaxoSmithKline 15

HSNi LLC

$100,000 – $249,999

Arthritis Foundation, Inc. 4

AstraZeneca LP 12

Daiichi Sankyo, Inc. 4

Eisai Inc. 7

Flexion Therapeutics, Inc. 2

Forest Laboratories, Inc. 3

Foundation for Burkitt Lymphoma Research

Fujirebio 2

Grifols 2

Healthcare Information and Management Systems Society 2

Ikaria, Inc.

Institut De Recherches Internationales Servier 4

Ann Lurie 2

Mr. and Mrs. Joel S. Marcus 3

Merck Serono

Nippon Zoki Pharmaceuticals Co., Ltd. 2

Novo Nordisk A/S 3

The Bernard Osher Foundation 5

Piramal Imaging, GmbH 3

Roche 6

George and Trish Vradenburg 2 Co-Founders USAgainst Alzheimer’s

$50,000 – $99,999

Actelion Pharmaceuticals Ltd. 3

Alexandria Real Estate Equities, Inc.

American Association for Dental Research

AXA Research Fund 2

Dairy Research Institute 3

Geoffrey Beene Foundation Alzheimer’s Initiative

All Foundation for the NIH (FNIH)

donors play a critical role in providing the

resources that are vital to our success.

Unrestricted gifts allow us the flexibility

to place them where they are most

needed, from supporting core operations

to developing new partnerships and

emerging program ideas. Donors also can

choose to restrict their gifts to one area

of interest, such as a biomedical research

program; a fellowship, lecture or

symposium that trains scientists and

helps them build their careers; or a

specific laboratory or area of scientific

research at the NIH.

The FNIH manages all private gifts

with care and efficiency. Of every

dollar spent, 94 cents are used to

support programs and just six cents

for administration and fundraising.

We gratefully acknowledge the

following donors and partners who made

gifts or pledges of $500 or more during

2013. Every attempt is made to list donors

according to their wishes. Please call

301.402.5311 if you have any questions.

Our Donors

[x] Superscript indicates number of years of consecutive giving.For a more complete list of donors, funds and endowments,

visit fnih.org/about/foundation/annual-reports

In 2013, FNIH received its seventh

consecutive four-star rating by Charity

Navigator. This top ranking recognizes

that we execute our mission in a

“fiscally responsible way, and

outperform most other charities.”

Our Donors


Howard Hughes Medical Institute 2

New England Biolabs 5

Perrigo Company plc 2

PhRMA Foundation 6

Promega Corporation 3

Regeneron Pharmaceuticals, Inc.

Mrs. Lily Safra 12

$25,000 – $49,999

American Society for Bone and Mineral Research

Bausch & Lomb Incorporated 3

Bayer HealthCare Pharmaceuticals Inc.

BioClinica, Inc. 4

Biotechnology Industry Organization 6

Colgate-Palmolive Company

Danskin

James H. and Christina W. Donovan 2

GE Healthcare

Iconix Brand Group In honor of Ari Goldman

IXICO Ltd. 2

Howard H. and Jacqueline K. Levine 3

Meso Scale Diagnostics, LLC. 5

Mr. and Mrs. Paul M. Montrone 16

NeuroRx 2

Otsuka American Pharmaceutical, Inc.

Andrew & Lillian A. Posey Foundation

Bill and Giuliana Rancic

SoBran, Inc. 3

SYNARC Inc. 6

Trius Therapeutics, Inc. 3

$10,000 – $24,999

Janet B. Abrams 5 In memory of Bernard Abrams

Alzheimer’s Drug Discovery Foundation

American College of Medical Genetics and Genomics

AMS Foundation for the Arts, Sciences and Humanities 9

Basilea Pharmaceutica International Ltd. 3

Peter D. and Karen N. Bell 2

Judy Belous In memory of Effie Loomis

Buffy and William Cafritz 10

Chiesi Farmaceutici S.p.A. 4

Timothy Choate

Brad Cox In honor of Ari Goldman

Crescendo Bioscience, Inc. 2

Friends of Cancer Research 4

Miles Gilburne and Nina Zolt 3

Hogan Lovells US LLP In honor of John Porter

Estate of Jack Gramlich 3

Freda C. Lewis-Hall, M.D., F.A.P.A.

LUNGevity Foundation

Mars, Incorporated

Steve and Sherry Mayer

Mitsubishi Tanabe Pharma Corporation

Drs. Martin J. and Ann Murphy 8

In honor of Charles and Ann Sanders

Myriad RBM

Nabriva Therapeutics AG 3

Nestlé USA Inc.

Bob and Sally Newcomb 3

Nichols Family 4

OfficeMax Incorporated

Steven and Jann Paul 3

PepsiCo, Inc.

RottaPharm I Madaus 3

Dame Jillian Sackler 11

Dr. and Mrs. Charles A. Sanders 17

Jane M. Sayer, Ph.D. 12

Dr. Ellen V. and Mr. Gerald R. Sigal 11 In honor of John Porter

Simon Property Group 4

The Association for Frontotemporal Degeneration

United States Pharmacopeial Convention 3

USAgainst Alzheimer’s Network

$5,000 – $9,999

Anonymous

American Diabetes Association 4

American Orthopaedic Society for Sports Medicine

Luther W. Brady, M.D. 7

California Dairy Research Foundation

Esther and James H. Cavanaugh 6

Centre for Proteomic & Genomic Research

Durata Therapeutics, Inc.

Foundation for Health Improvement and Technology

Marjorie D. Fuller In memory of Jean Fuller

General Mills, Inc.

Carol-Ann Harris

Laura and Chris Hazzard 5

In memory of Richard Curtin

Mike and Beth Hunkapiller 2

Kite Pharma, Inc. 2

Barbara Lazio In memory of Carol Scher

Kelly and Adam Leight

Metabolon, Inc.

[x] Superscript indicates number of years of consecutive giving.

Our Donors


Dr. and Mrs. Garry A. Neil 2

Erik F. Neva 2

Kristin Neva 2

Radiological Society of North America 5

Research!America In honor of John Porter

Robert E. Roberts, Ph.D. 5 In memory of Barbara Roberts

Nina Solarz 4 In memory of Stephen Solarz

University of British Columbia 3

Marica and Jan Vilcek 2

Steve and Chris Wilsey 5

Drs. Elias A. and Nadia Zerhouni

$2,500 – $4,999

Anonymous

Alliance for Aging Research 2

Ronald and Barbara Berke 4

In memory of Jennifer Berke

Gregg Bevensee 4

ChemoCentryx, Inc.

Anthony S. Fauci, M.D. and Christine Grady, Ph.D.

Jim Fisher

Joseph H. and Cheryl L Kott In honor of Temptime’s 25th anniversary

Donna Nichols 4

PNC Foundation

Lenore R. Salzman 16

SOHO Publishing Company 2

SunTrust Banks, Inc. 3

Samuel O. Thier, M.D. and Paula Thier 8

Alexander Trebek

Ullmann Family Foundation 5

Zerhouni Group LLC

$1,000 – $2,499

Anonymous (3)

Ronald A. and June L. Ahrens 2 In honor of Xavier Martin

Alnor Oil Company

Dr. and Mrs. William G. Barsan 4

Raghu Bellary

BH III LLC In honor of Ari Goldman

Dr. Kathy and Mr. Zachary T. Bloomgarden 5

Mr. Charles Cerf and Dr. Cynthia E. Dunbar 3

Mark Chee, Ph.D. 2

Joe Bergera and Alice Cho

Thomas and Corrie Colter In memory of Malcolm McDuffie

Stewart Daniels 5

Robert and Betsey Drucker 2

Marianne E. Durkin In honor of Miller & Rider Group

Marilyn B. Einstein and Steven P. Sim

Jack A. Elias, M.D.

The Essence of Red Committee 3

Shirley Evans In memory of Eleanor Frierson

Ronald G. Evens, M.D. 7

In honor of John Gallin

Joseph M. Feczko, M.D. and Leighton K. Gleicher 6

James M. Felser, M.D. 4

Shelagh Ferguson-Miller, Ph.D.

Drs. Ernesto I. and Maria C. Freire 2

Paul J. Gattini 2

Stanley and Eve Geller 3

Peggy J. Gerlacher 16

In memory of John Gerlacher

Eli Glatstein 10

Jane O. Graham 3

Margaret Grieve In honor of Nina Solarz’ birthday

Gary and Lynn Grossman 3

Kay A. Hart 3

Harley Anderson Haynes, M.D. 4

Eric Hirschhorn and Leah Worthham 3

Eva C. Holtz 4

IQ Solutions 4

Kalidex Pharmaceuticals, Inc.

Bernard H. and Georgina E. Kaufman 4

U.S. Senator Amy Klobuchar

Sherry Lansing and William Friedkin

Jonathan D. Levine 3

Jean Linton 11

Edison T. Liu, M.D., Ph.D.

John Madden

Debbie Magids In honor of Ari Goldman

Margaret and James Malaro

Martin Goldman, L.L.C. In honor of Ari Goldman

Ruth O. Mutch

Amy and John Porter 14

Sunny Raspet

Charles P. Rogers Beds

Robert and Marjorie Rosenberg 3

Estate of Frances H. Saupe 6

Robert C. and Dawn W. Schiff

Dr. and Mrs. Richard B. Silverman

Mark A. Spiteri 7

Russell W. Steenberg and Patricia Colbert

Lynda Swann In honor of Lanier Swann

Our Donors


Temptime Corporation 3

The Drs. Tremoulet 5

Jon and Kristin Vaver 6

Howard M. and Nancye C. Weisberg 5

Dr. Ann F. Welton 6

Stephanie J. Whang, M.D.

Michael and Lisa Nichols Whitten

Stewart K. Wilson 2

$500 – $999

Anonymous (3)

Drs. Bryan and Donna Arling 9

Association of American Medical Colleges 2 In memory of Rod Ulane

Dr. and Mrs. Paul A. Berg

Robert A. Bergman 3

In memory of Arthur Schatzkin

Berroco, Inc. 2

Bnai Mitzvah Project 2013

Dan Balliet and Jan Carlson 5

Susan Castle In honor of Ari Goldman

Classic Elite Yarns

The Community Foundation for Greater Atlanta, Inc.

Janet S. DeGilio 4

James and Karen Gavic 4

Michael and Linda Goone

Ken and Yvette Guidry 7

Andrea Haslinger In honor of Gregory Papp and Lindsay Bailey

Henry Haslinger In honor of Gregory Papp and Lindsay Bailey

Amy W. Hawthorne

Brian J. and Darlene Heidtke

Abigail Holtz

Arthur C. and Susan C. Horowitz 2

David Horowitz In honor of Ari “Prefontaine” Goldman

Jimmy Beans Wool 2

Max Kantzer In memory of Henry Kantzer & In honor of Ari Goldman

Charles E. Kaufman Medical Fund 2

Ronald L. Krall, M.D. 2

In memory of Vivian Krall

Jeremy Krasner 2

Arnold Lakind

Erica Joyce Lam 2

Dr. and Mrs. Ronald W. Lamont-Havers 4

Wei Li

Russell C. Libby, M.D. and Mary Schmidt Libby, M.D. 2

London OpCo LLC

Mattlin Foundation 5

Charles McCormick 4

Luke McCrone 2

The McDuffie Family In memory of Malcolm McDuffie

Reverend and Mrs. Robert H. Naylor 4

New Belgium Brewing Co., Inc.

Northrop Grumman Corporation

Glen and Beverley Norton

Dr. Gilbert S. Omenn and Mrs. Martha Darling 3

Matthew W. O’Neill 5

Matt and Robyn Nichols Painter 2 In memory of Jay Nichols

George Rudman In honor of Ari Goldman

Dr. Michael Ryan and Dr. Linda Ryan

Howard K. Schachman 9

In memory of Ethel Schachman

Charles and Chris Sellers

Danny Shively 5

Walt and Rachel Sirene 2

Skacel Collection 2

Richard I. and Anastasia Smith

Shannon Stafford

Marta M. Ulane & Family In memory of Rod Ulane

Richard and Tracy Nichols Waggoner In memory of Jay Nichols

David Wholley and Mary M. O’Crowley 2

Fred C. Williamson

Matthew Zimmerman 4

[x] Superscript indicates number of years of consecutive giving.


Board of DirectorsCharles A. Sanders, M.D. (Chairman)

Retired Chairman and CEO, Glaxo, Inc.

Mrs. William McCormick Blair, Jr. (Secretary)

Director Emeritus, Albert and Mary

Lasker Foundation

Kathy Bloomgarden, Ph.D.

Chief Executive Officer, Ruder Finn, Inc.

Mrs. William (Buffy) N. Cafritz

Trustee, The John F. Kennedy Center for

the Performing Arts

Mr. James H. Donovan

Partner, Goldman Sachs & Company;

Adjunct Professor, University of Virginia

Joseph Feczko, M.D.

Retired Senior Vice President & Chief

Medical Officer, Pfizer Inc.

Maria C. Freire, Ph.D.

President and Executive Director,

Foundation for the National Institutes

of Health

Mr. Miles Gilburne

Managing Member, ZG Ventures, LLC

Paul L. Herrling, Ph.D.

Chairman, Novartis Institute for

Tropical Disease

Ronald L. Krall, M.D.

Former Senior Vice-President and

Chief Medical Officer, GlaxoSmithKline

Ms. Sherry Lansing

Chief Executive Officer, The Sherry

Lansing Foundation

Freda C. Lewis-Hall, M.D.

Chief Medical Officer, Senior Vice President,

Pfizer Inc.

Edison T. Liu, M.D., Ph.D.

President and Chief Executive Officer,

The Jackson Laboratory

Ms. Ann Lurie

Lurie Holdings, Inc., Ann & Robert H.

Lurie Foundation

Mr. Joel S. Marcus

Chairman, CEO and Founder,

Alexandria Real Estate Equities, Inc.

Mr. Steven C. Mayer

Former CEO and Co-Founder,

CoGenesys, Inc.

Paul M. Montrone, Ph.D. (Treasurer)

Chairman, Perspecta Trust

Martin J. Murphy, Jr., Ph.D.

Chairman & Chief Executive Officer,

AlphaMed Consulting, Inc.

Garry A. Neil, M.D.

Global Head R&D, Medgenics, Inc.

Steven M. Paul, M.D.

Director, Helen and Robert Appel

Alzheimer’s Disease Research Institute,

Weill Cornell Medical College

The Honorable John Edward Porter (Vice Chairman for Policy)

Hogan Lovells US, LLP

Mrs. Jillian Sackler, D.B.E.

President and CEO, AMS Foundation for

the Arts, Sciences and Humanities

Mrs. Lily Safra

Chairwoman, The Edmond J. Safra

Philanthropic Foundation

Ellen V. Sigal, Ph.D.

Chairperson, Friends of Cancer Research

Solomon H. Snyder, M. D. (Vice Chairman for Science)

Distinguished Service Professor of

Neuroscience, Johns Hopkins University

School of Medicine

Ms. Nina K. Solarz

Former Executive Director of Peace Links

and the Fund for Peace

Samuel O. Thier, M.D.

Professor of Medicine and Health Care

Policy, Emeritus, Harvard Medical School,

Massachusetts General Hospital

Anne Wojcicki

Chief Executive Officer and Co-Founder,

23andMe

HONORARY DIRECTORS

Luther W. Brady, M.D.

Distinguished University Professor,

Drexel University College of Medicine

Patrick C. Walsh, M.D.

University Distinguished Service

Professor of Urology, Johns Hopkins

Medical Institutions

DIRECTOR EMERITUS

Paul Berg, Ph.D.

Cahill Professor in Biochemistry (Emeritus),

Stanford University School of Medicine

EX-OFFICIO

Francis S. Collins, M.D., Ph.D.

Director, National Institutes of Health

Margaret A. Hamburg, M.D.

Commissioner, Food and Drug

Administration

Our Staff

PRESIDENT’S OFFICE

Maria C. Freire, Ph.D.

President and Executive Director

Ann Ashby, M.B.A.

Deputy Executive Director

Andrea Baruchin, Ph.D.

Senior Advisor to the President

Erika Tarver

Senior Project Manager

Felicia Gray

Executive Assistant

Liz Johns

Executive Assistant

Kathy Guire

Operations Officer

FINANCE

Julie Tune, C.P.A., C.F.E.

Chief Financial Officer

Eva Coyne, C.P.A.

Controller

Cathy Martin, C.P.A.

Senior Accountant

Noemi B. Rodriguez

Staff Accountant

Peggy J. Gerlacher

Operations Associate

EVENTS AND MARKETING

Laura Payne

Director

Jolie Mak

Events Manager

Jasmin Miles

Senior Events Coordinator

Andrea Hickman

Events Coordinator

Kai Yee

Digital Administrator

DEVELOPMENT

Julie Wolf-Rodda, M.A.

Director of Development

Renee Bullion, M.P.A.

Partnership Development Officer

Elizabeth Dobbins


Rob Drucker, J.D., M.S.


Caite Gilmore


Jennifer Ilekis, M.P.A.


Paris L.A. Moore


Asante Shakuur


Will Tolentino

Development Systems Administrator

Anne Bradfield

Development Assistant

Will Whitaker

Development Intern

SCIENCE ADMINISTRATION

Stephanie James, Ph.D.

Director of Science and Director, Grand

Challenges in Global Health

Michael Gottlieb, Ph.D.

Deputy Director of Science

Dennis Lang, Ph.D.

Senior Program Coordinator, MAL-ED

(Contractor)

Karen Tountas, Ph.D.

Scientific Program Manager, MAL-ED

Susan Powell, M.T.S.

Senior Grants Manager

Susan Wiener, M.A.

Senior Project Manager

Gail Levine, M.A., C.R.C.C.

Scientific Program Manager

Anna Sambor, M.S.

Program Manager

Tiffany Francis

Executive Assistant

BIOMARKERS CONSORTIUM

David Wholley, M.S.

Director

Maria Vassileva, Ph.D.

Senior Scientific Program Manager,

Metabolic Disorders

Sonia Pearson-White, Ph.D.

Scientific Program Manager, Cancer

Judy Siuciak, Ph.D.

Scientific Program Manager, Neuroscience

Steven C. Hoffmann

Scientific Program Manager, Inflammation

and Immunity

Jessica Ratay, M.S.

Clinical Project Manager

Cheryl Melencio

Executive Assistant

PROFILE

The Foundation for the National Institutes of Health procures funding and

manages alliances with public and private institutions in support of the

mission of the NIH, the premier medical research agency. The Foundation,

also known as the FNIH, works with its partners to accelerate biomedical

research and strategies to fight against diseases in the United States and

across the world. The FNIH organizes and administers research projects;

supports education and training of new researchers; organizes educational

events and symposia; and administers a series of funds supporting a wide

range of health issues. Established by Congress in 1996, the FNIH is a

not-for-profit 501(c)(3) charitable organization. For additional information

about the FNIH, please visit www.fnih.org.

PHOTO CREDITS

Page 1: Maria C. Freire, Ph.D. by Robert Burke Photography

Page 4: Vernon Doucette for Boston University Photography

Page 5, left: National Cancer Institute

Page 6: Dennis Lang, FNIH

Page 8: Centers for Disease Control and Prevention Public Health Image Library

Page 9, left: Eliminate Dengue

Page 9, right: courtesy Dr. Glaab

DESIGN

Rector Communications, Inc., Philadelphia, PA | www.rector.com

Foundation for the National Institutes of Health

9650 Rockville Pike

Bethesda, MD 20814-3999

fnih.org

FSC BUG

LOCATION

(DOES NOT

PRINT)

new pathways to discovery - home | fnih 2013 annual report.pdfforging uncommon collaborations a new...

Documents